Cardiopoietic cell therapy for advanced ischaemic heart failure: Results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

European Heart Journal

Volumn 38, Issue 9, 2017, Pages 648-660

  Bartunek, Jozef ^a   Terzic, Andre ^b   Davison, Beth A ^c   Filippatos, Gerasimos S ^d   Radovanovic, Slavica ^e   Beleslin, Branko ^f   Merkely, Bela ^g   Musialek, Piotr ^h   Wojakowski, Wojciech ⁱ   Andreka, Peter ^j   Horvath, Ivan G ^k   Katz, Amos ^l   Dolatabadi, Dariouch ^m   El Nakadi, Badih ^m   Arandjelovic, Aleksandra ⁿ   Edes, Istvan ^o   Seferovic, Petar M ^p   Obradovic, Slobodan ^q   Vanderheyden, Marc ^a   Jagic, Nikola ^r   Petrov, Ivo ^s   Atar, Shaul ^t,u   Halabi, Majdi ^u   Gelev, Valeri L ^s   Shochat, Michael K ^v   Kasprzak, Jaroslaw D ^w   Sanz Ruiz, Ricardo ^x   Heyndrickx, Guy R ^a   Nyolczas, Noemi ^y   Legrand, Victor ^z   Guédès, Antoine ^aa   Heyse, Alex ^ab   Moccetti, Tiziano ^ac   Fernandez Aviles, Francisco ^x   Jimenez Quevedo, Pilar ^ad   Bayes Genis, Antoni ^ae   Hernandez Garcia, Jose Maria ^af   Ribichini, Flavio ^ag   Gruchala, Marcin ^ah   Waldman, Scott A ^ai   Teerlink, John R ^aj   Gersh, Bernard J ^b   Povsic, Thomas J ^ak   Henry, Timothy D ^al   Metra, Marco ^am   Hajjar, Roger J ^an   Tendera, Michal ⁱ   Behfar, Atta ^b   Alexandre, Bertrand ^ao   Seron, Aymeric ^ao   Stough, Wendy Gattis ^ap   Sherman, Warren ^ao   Cotter, Gad ^c   Wijns, William ^a,aq   more..

^a OLV HOSPITAL   (Belgium)

^b MAYO CLINIC   (United States)

^c Momentum Research Inc   (United States)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e Univ Clin Bezanijska Kosa Belgrade   (Yugoslavia)

^f UNIVERSITY OF BELGRADE   (Serbia)

^g SEMMELWEIS UNIVERSITY   (Hungary)

^h JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

ⁱ MEDICAL UNIVERSITY OF SILESIA   (Poland)

^j Hungarian Institute of Cardiology   (Hungary)

^k UNIVERSITY OF PÉCS   (Hungary)

^l BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^m Centre Hospitalier Universitaire de Charleroi   (Belgium)

ⁿ Clinical Hospital Centre Zvezdara   (Serbia)

^o UNIVERSITY OF DEBRECEN   (Hungary)

^p UNIVERSITY OF BELGRADE   (Serbia)

^q Serbia   (Serbia)

^r CLINICAL CENTER KRAGUJEVAC   (Serbia)

^s UNIVERSITY OF SOFIA   (Bulgaria)

^t WESTERN GALILEE HOSPITAL   (Israel)

^u BAR ILAN UNIVERSITY   (Israel)

^v HILLEL YAFFE MEDICAL CENTER   (Israel)

^w MEDICAL UNIVERSITY OF LODZ   (Poland)

^x HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^y Medical Centre   (Hungary)

^z UNIVERSITY OF LIÈGE   (Belgium)

^aa UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^ab AZ Glorieux ^*  (Belgium)

^ac DIVISION OF CARDIOLOGY   (Switzerland)

^ad HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^ae UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^af HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^ag UNIVERSITY OF VERONA   (Italy)

^ah MEDICAL UNIVERSITY OF GDANSK   (Poland)

^ai THOMAS JEFFERSON UNIVERSITY   (United States)

^aj UNIVERSITY OF CALIFORNIA   (United States)

^ak DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^al CEDARS SINAI MEDICAL CENTER   (United States)

^am SPEDALI CIVILI   (Italy)

^an MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^ao CELYAD   (Belgium)

^ap CAMPBELL UNIVERSITY   (United States)

^aq NATIONAL UNIVERSITY OF IRELAND   (Ireland)

more..

Author keywords

Cardiopoiesis; Cardiovascular disease; Disease severity; Marker; Precision medicine; Regenerative medicine; Stem cell; Target population

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; TROPONIN T;

ADULT; AORTA COARCTATION; APHASIA; ARTICLE; ASCENDING AORTA SURGERY; BONE MARROW CELL; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOPOIETIC CELL THERAPY; CARDIOVASCULAR MORTALITY; CELL THERAPY; CLINICAL OUTCOME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE ISCHEMIA; HEART TAMPONADE; HEART TRANSPLANTATION; HEART VENTRICLE TACHYCARDIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHAM PROCEDURE; STEM CELL EXPANSION; SUDDEN CARDIAC DEATH; TRANSIENT ISCHEMIC ATTACK; AGED; CLINICAL TRIAL; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85016214953     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw543     Document Type: Article

References (32)

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200.
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de FS, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jimenez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER III, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation 2016;133:e38-360.
3. Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-analytic approach. J Am Coll Cardiol 2010;56:392-406.
4. Braunwald E. The war against heart failure: the Lancet lecture. Lancet 2015;385:812-824.
5. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ. Cell therapy for cardiac repair-lessons from clinical trials. Nat Rev Cardiol 2014;11:232-246.
6. Menasche P, Vanneaux V. Stem cells for the treatment of heart failure. Curr Res Transl Med 2016;64:97-106.
7. Cogle CR, Wise E, Meacham AM, Zierold C, Traverse JH, Henry TD, Perin EC, Willerson JT, Ellis SG, Carlson M, Zhao DX, Bolli R, Cooke JP, Anwaruddin S, Bhatnagar A, da GC-H, Grant MB, Lai D, Moye L, Ebert RF, Olson RE, Sayre SL, Schulman IH, Bosse RC, Scott EW, Simari RD, Pepine CJ, Taylor DA. Detailed analysis of bone marrow from patients with ischaemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ Res 2014;115:867-874.
8. Marban E, Malliaras K. Mixed results for bone marrow-derived cell therapy for ischaemic heart disease. JAMA 2012;308:2405-2406.
9. Terzic A, Behfar A. Regenerative heart failure therapy headed for optimization. Eur Heart J 2014;35:1231-1234.
10. Assmus B, Walter DH, Seeger FH, Leistner DM, Steiner J, Ziegler I, Lutz A, Khaled W, Klotsche J, Tonn T, Dimmeler S, Zeiher AM. Effect of shock wavefacilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA 2013;309:1622-1631.
11. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, Marban L, Mendizabal A, Cingolani E, Johnston PV, Gerstenblith G, Schuleri KH, Lardo AC, Marban E. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 2014;63:110-122.
12. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da SJ, Anderson E, Schwarz R, Mendizabal A, Hare JM. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischaemic cardiomyopathy: the TAC-HFT randomized trial. JAMA 2014;311:62-73.
13. Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J, Desai AS, Recker D, DeMaria A. Ixmyelocel-T for patients with ischaemic heart failure: A prospective randomised double-blind trial. Lancet 2016;387:2412-2421.
14. Terzic A, Behfar A. Stem cell therapy for heart failure: ensuring regenerative proficiency. Trends Cardiovasc Med 2016;26:395-404.
15. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C, Gaussin V, Homsy C, Bartunek J, Terzic A. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol 2010;56:721-734.
16. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El NB, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013;61:2329-2338.
17. Behfar A, Latere JP, Bartunek J, Homsy C, Daro D, Crespo-Diaz RJ, Stalboerger PG, Steenwinckel V, Seron A, Redfield MM, Terzic A. Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ Cardiovasc Interv 2013;6:710-718.
18. Bartunek J, Davison B, Sherman W, Povsic T, Henry TD, Gersh B, Metra M, Filippatos G, Hajjar R, Behfar A, Homsy C, Cotter G, Wijns W, Tendera M, Terzic A. Congestive heart failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. Eur J Heart Fail 2016;18:160-168.
19. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med 1999;18:1341-1354.
20. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics 2004;5:465-481.
21. Jackson N, Atar D, Borentain M, Breithardt G, van Eickels M, Endres M, Fraass U, Friede T, Hannachi H, Janmohamed S, Kreuzer J, Landray M, Lautsch D, Le Floch C, Mol P, Naci H, Samani N, Svensson A, Thorstensen C, Tijssen J, Vandzhura V, Zalewski A, Kirchhof P. Improving clinical trials for cardiovascular diseases: A position paper from the Cardiovascular Roundtable of the European Society of Cardiology. Eur Heart J 2016;37:747-754.
22. Bartunek J, Sherman W, Vanderheyden M, Fernandez-Aviles F, Wijns W, Terzic A. Delivery of biologics in cardiovascular regenerative medicine. Clin Pharmacol Ther 2009;85:548-552.
23. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res 2015;116:1361-1377.
24. Janssens S. Stem cells in the treatment of heart disease. Annu Rev Med 2010;61:287-300.
25. Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 2015;116:1413-1430.
26. Behfar A, Terzic A. Stem cell in the rough: repair quotient mined out of a bone marrow niche. Circ Res 2014;115:814-816.
27. Bax JJ, Schinkel AF, Boersma E, Elhendy A, Rizzello V, Maat A, Roelandt JR, van der Wall EE, Poldermans D. Extensive left ventricular remodeling does not allow viable myocardium to improve in left ventricular ejection fraction after revascularization and is associated with worse long-term prognosis. Circulation 2004;110: II18-II22.
28. Braun J, Bax JJ, Versteegh MI, Voigt PG, Holman ER, Klautz RJ, Boersma E, Dion RA. Preoperative left ventricular dimensions predict reverse remodeling following restrictive mitral annuloplasty in ischaemic mitral regurgitation. Eur J Cardiothorac Surg 2005;27:847-853.
29. Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P, Shinn T, Solomon S, Steinberg JS, Wilber D, Barsheshet A, McNitt S, Zareba W, Klein H. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011;124:1527-1536.
30. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-2559.
31. Lazar AA, Bonetti M, Cole BF, Yip WK, Gelber RD. Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP. Clin Trials 2016;13:169-179.
32. Terzic A, Pfenning MA, Gores GJ, Harper CM Jr. Regenerative medicine buildout. Stem Cells Transl Med 2015;4:1373-1379.